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Abstract MicroRNA (miRNA) dysregulation is causally
related to cancer development and progression, and recent
reports have revealed that DNA methylation constitutes an
important mechanism for miRNA deregulation in cancer.
MiR-129-2 has been reported to be down-regulated and
functions as a tumor suppressor in a few human cancers.
However, the involvement of miR-129-2 in the pathology
of glioma and the mechanism underlying miR-129-2
regulation in glioma cells remain unclear. In this study, we
performed quantitative PCR to investigate the level of
miR-129-2 in 21 pairs of glioma tumors and matched ad-
jacent tissues and found that miR-129-2 is down-regulated
in glioma tumors. In vitro cell growth, apoptosis, cell mi-
gration, and invasion assays revealed that miR-129-2
functions as a tumor suppressor in glioma cells. Luciferase
reporter assay found that miR-129-2 could directly target
high-mobility group box 1 (HMGB1) and inhibit its ex-
pression in glioma cells. Methylation-specific PCR found
that DNA methylation in upstream regions of miR-129-2
occured more frequently in cancer tissues than in adjacent
tissues. Demethylation of miR-129-2 by 5-aza-20-deoxy-
cytidine treatment and quantitative PCR analysis revealed
that miR-129-2 expression is epigenetically regulated in
glioma cells. Taken together, our data suggested that miR-
129-2 functions as a tumor suppressor in glioma cells by
directly targeting HMGB1 and is down-regulated by DNA
methylation, which may provide a novel therapeutic strat-
egy for treatment of glioma.
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Introduction
Glioma is the majority of malignant brain tumors and rep-
resents a serious health problem worldwide [1]. Although
glioma has been widely studied, the molecular mechanisms
underlying its pathology remain poorly understood.
MicroRNAs (miRNAs) are a group of endogenous small
noncoding RNAs that are involved in the posttranscrip-
tional regulation of gene expression through imperfect
base-pairing with the 30untranslated region (30UTR) of
target mRNAs [2, 3]. MiRNAs have been found to be
critical in numerous biological functions such as cell pro-
liferation, differentiation, and apoptosis [4]. Accumulated
evidence has also revealed that miRNAs are deregulated in
various diseases, including human cancer [5–7].
MiR-129 family members have been reported to function
as a tumor suppressor in a variety of human cancers. For
example, miR-129was down-regulated in gastric cancer and
increased miR-129 in gastric cancer cells resulted in sig-
nificant G0/G1 phase arrest [8]. In esophageal carcinoma
cells, miR-129-2 suppresses cell proliferation and migration
through down-regulation of SOX4 expression [9]. However,
the function of miR-129 and the mechanism underlying
glioma carcinogenesis remain unclear. In this study, we
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examined the expression of miR-129-2 in glioma tumors and
cell lines and investigated the roles of miR-129-2 in glioma
cells. We found that miR-129-2 was down-regulated in
glioma tumors and cell lines, while enforced expression of
miR-129-2 repressed glioma cell growth, cell migration, and
invasion and promoted cell apoptosis in vitro. Luciferase
reporter assay further revealed thatmiR-129-2 could directly
target and inhibit high-mobility group box 1 (HMGB1),
which has been found to be up-regulated and involved in the
pathogenesis of many kinds of human cancers [10], and
knockdown of HMGB1 inhibits cell migration and invasion
of glioma cells in vitro in our study.
Epigenetic modifications are closely associated with
gene expression. For example, promoter hypermethylation
is thought to be a mechanism to down-regulate tumor
suppressor genes in human cancers [11]. Recently, miR-
NAs whose expression is repressed by DNA methylation
have been reported in a few human cancers [12–14]. As for
miR-129-2, it has been reported to be frequently methy-
lated in hepatocellular carcinoma and gastric cancer [15–
17], and methylation-mediated repression of miR-129-2
enhanced oncogenic SOX4 expression in HCC [18], gastric
cancer [19], and endometrial cancer [20]. In this study, to
investigate whether the down-regulation of miR-129-2
originates from the hypermethylation of the miR-129-2
genomic region, we analyzed the DNA methylation of CpG
island in the upstream region of miR-129-2 in glioma tu-
mors and found that down-regulation of miR-129-2 in
glioma tumors might be due to the hypermethylation of
CpG sequences in its upstream region.
Materials and methods
Tissue samples and cell lines
Clinical tumor tissues and the corresponding adjacent tissues
were collected from 21 glioma patients from Xiangya
Hospital and were stored at -80 C until RNA extraction.
Four human glioma cell lines including A172, U251, U373,
U87, and a normal neuronal cell line primary human fetal
glial (PHFG cell) were preserved in our laboratory and
maintained in DMEM or RPMI 1640 with 10 % fetal bovine
serum (FBS) in a humidified atmosphere of 5 % CO2 at
37 C. The Clinical Research Ethics Committee of Central
South University approved the research protocols, and
written informed consent was obtained from the participants.
RNA extraction and reverse-transcribed
quantitative PCR (RTq-PCR)
Total RNA was extracted from tissues and cell lines using
Trizol reagent (Invitrogen, CA, USA) according to the
manufacturer’s instructions. 1 lg of total RNA was re-
versely transcribed using oligo (dT) 18 as the RT primers
for reverse transcription of mRNA and a stem-loop RT
primer for the reverse transcription of miRNA. Quantita-
tive PCR was then performed using ABI 7500 Sequence
Detection System (Life Technologies, NY, USA). For
mRNAs, the data were normalized using the endogenous
b-actin as control. The specific primers for b-actin and




GGTT-30. To quantify the miR-129-2 expression levels, the
expression of small nuclear U6 was used as internal con-
trol. The specific primers for miRNA-129b and U6 were
purchased from GeneCopoeia. All experiments were per-
formed in triplicate. Relative expression levels were cal-
culated using the 2-DDCt method.
MTT assay
Cells were allowed to grow in 96-well plates with 5000 cell
per well and incubated for 24, 48, and 72 h and then MTT
(10 mg/ml) was added to the cells and incubated for 3 h.
The reaction was then terminated by removal of the su-
pernatant followed by adding 200 ll of DMSO. After 2-h
incubation, the optical density at 570 nm of each well was
measured with a microplate reader (Bio–Rad).
Cell migration and invasion assays
Cell migration was assessed by wound-healing assay. An
artificial wound was scratched on a confluent cell mono-
layer without FBS using sterile tips, and wound-healing
images were taken at 24 and 48 h later. Cell invasion was
assessed using transwell invasion chambers coated with
matrigel (BD Biosciences, Franklin Lakes, NJ, USA).
0.2 ml of cells suspended in serum-free medium was added
into the upper chamber. The lower chamber was filled with
500 ul of RPMI 1640 or DMEM medium with 10 % FBS
as the nutritional attractant. 24 h later, cells remaining on
the upper side of the membrane were removed, and cells
that migrated through the membrane were fixed with 75 %
alcohol and stained with crystal violet, and the invasive
cells were counted and imaged using an inverted micro-
scope (Nikon, Japan).
Cell cycle and apoptosis by flow cytometric analysis
Cell cycle analysis was performed by flow cytometric
(FCM) analysis. The cells were fixed in 70 % ethanol,
washed with PBS, and resuspended in staining solution
(50 lg/ml of propidium iodide, 1 mg/ml of RNase A,
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0.1 % Triton X-100 in PBS). After incubation for 30 min at
4 C, the stained cells were then analyzed with a flow
cytometer (Beckman Coulter). For apoptosis assay, cells
were collected and transferred to 60 mm dishes. The cell
apoptosis ratio was analyzed using the Annexin V-FITC
Apoptosis Detection kit (BD Biosciences, San Diego, CA),
according to the manufacturer’s instructions.
Western blotting
Total cellular extracts were prepared with lysis buffer, and
approximately 50 lg of total protein was separated by
SDS-PAGE, transferred to a PVDF membrane, and incu-
bated with the antibodies, followed by the HRP-conjugated
secondary antibody. Signals were visualized using ECL
substrates (Millipore, USA). The protein bands were vi-
sualized using the enhanced chemiluminescence (ECL)
detection kit (Amersham) as recommended by the
manufacturer. b-Actin was used for normalization. Anti-
bodies of HMGB1 and b-actin were obtained from Ab-
zoom (Abzoom, USA).
Luciferase reporter assays
The 30UTR of the wild-type HMGB1 and a variant con-
taining mutations in the putative miR-129-2 binding sites
(Fig. 3a) were inserted downstream of the firefly luciferase
reporter in the psiCHECK-2 vector (Promega, Madison, WI,
USA). U373 and U87 cells were seeded into 24-well plates
for 24 h before transfection. Cells were then co-transfected
with the reporter vector (psiCHECK-2-HMGB1-WT-30UTR
or psiCHECK-2-HMGB1-Wut-30UTR) and miR-129-2
mimics or scrambled mimics using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA). Cells were harvested, and
luciferase activity was detected using a dual-luciferase re-
porter assay system (Promega, Fitchburg, WI, USA) 48 h
after transfection. All experiments were performed in trip-
licate. The miR-129-2 mimics, miR-129-2 inhibitor, and
their scrambled mimics (negative control) were purchased
from Genechem (Shanghai, China).
Lentivirus infection and siRNAs
Lentiviruses containing miR-129-2 (Lv-miR-129) and
negative control (Lv-NC) were purchased from GeneChem
(Shanghai, China). Cells were cultured up to 70 % of the
plates and then added by a concentration of 2.4 9 105 TU/
well Lv-miR-129-2 or negative control lentivirus. Quanti-
tative PCR was then performed to determinate the ex-
pression levels of miR-129-2 and HMGB1 after being
infected for 6 days. The small interfering RNAs (siRNA)
targeting human HMGB1 mRNA and negative control
siRNA (si-NC) were purchased from Ruibobio (Guangz-
hou, China).
5-Aza-dC treatment
For demethylation study, U373 and U87 cells were treated
with 5-aza-20-deoxycytidine (5-Aza-dC, Sigma-Aldrich,
USA) at 0.5 mmol/l for 4 days. Culture medium containing
5-Aza-dC was replaced every 24 h.
DNA bisulfite modification and bisulfite-sequencing
PCR
Genomic DNA was obtained from tissues or cells using
DNA Extraction Mini Kit (TIANGEN Biotech, Beijing,
China) according to the manufacturer’s instructions. 1 lg
of genomic DNA was bisulfite treated and recovered with
EZ DNA Methylation-Gold kit (Zymo Research, CA,
USA) according to the manufacturer’s instructions. Bisul-
fite-sequencing PCR (BSP) for miR-129-2 was done using
ZymoTaqTM PreMix (Zymo Research) with the following
primers: 50-TGATAGGGAGATAGAGGGAT-30 (forward)
and 50-AACAAACTAAATCTCCCCAA-30 (reverse),
which amplify a 268-bp product under the conditions of
95 C for 10 min, followed by 40 cycles of 95 C for 30 s,
58 C for 30 s, and 72 C for 30 s. The BSP products
contained 22 CpG sites in the promoter region of miR-129-
2 and were cloned into the pUC18-T vector (Biodee,
Beijing, China). Twenty clones for each group were ran-
domly selected and sequenced by Shanghai Sangon Co
(Shanghai, China).
Methylation-specific PCR (MSP)
Methylation-specific PCR (MSP) primers detecting methy-
lated (M) or unmethylated (U) alleles of the miR-129-2
promoter were miR-129-2-MF, 50-TTTTAGTTCGTAT
TAATGAGTTGGC-30 and miR-129-2-MR, 50-AATCTC
TAAACAAATACAATTCGAA-30 for methylated alleles
and miR-129-2-UF, 50-TTAGTTTGTATTAATGAGTTGG
TGG-30 and miR-129-2-UR, 50-AATCTCTAAACAAATA
CAATTCAAA-30 for unmethylated alleles. MSP was per-
formed for 35 cycles (95 C for 30 s, 58 C for 30 s, and
72 C for 30 s). MSP primers were first checked for not
amplifying any unbisulfited DNA. PCR products were then
analyzed on a 2 % agarose gel. Samples with a stronger
band intensity than the negative control in the MSP were
regarded as methylated, and samples with no visible PCR
product were regarded as unmethylated.
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Results
MiR-129-2 was down-regulated in glioma tumors
and cell lines
To assess the expression of miR-129-2 in glioma cells,
RTq-PCR analysis was performed in 21 pairs of glioma
tissues and matched adjacent tissues. As shown in Fig. 1a,
the expression levels of miR-129-2 were significantly
down-regulated in glioma tumors compared with those in
matched adjacent tissues. Additionally, miR-129-2 ex-
pression levels in four glioma cell lines (A172, U251,
U373, and U87) were also decreased relative to the normal
neuronal cell line PHFG (Fig. 1b). Taken together, these
data suggest a potential link between loss of miR-129-2
and glioma pathology.
MiR-129-2 inhibits glioma cell growth and promotes
cell apoptosis in vitro
We then investigated the functional roles of miR-129-2 in
glioma cells. We constructed lentiviral vector expressing
pre-miR-129-2 (Lv-miR-129-2) or miR-129-2 antisense
(Lv-anti-miR-129-2) and infected U373 and U87 cells to
restore or inhibit miR-129-2 expression. RTq-PCR was
performed to confirm that miR-129-2 was restored in these
stable infected cells (Fig. 2a). We then investigated the
effect of miR-129-2 on cell proliferation, cell cycle, and
apoptosis, respectively. MTT assays indicated that the en-
hanced expression of miR-129-2 could significantly inhibit
cell proliferation compared to control group in U373 and
U87 cells (Fig. 2b). In addition, we found that miR-129-2
restoration increased the percentages of G1 (not sig-
nificantly) and G2 phase cells in U373 and U87 cells
(Fig. 2c) and promoted cell apoptosis (Fig. 2d), as deter-
mined by FCM analysis. In contrast, when endogenous
miR-129-2 was silenced, the cell proliferation (Fig. 2b)
and cell cycle (Fig. 2c) were significantly increased, and
cell apoptosis was suppressed (Fig. 2d). These results
suggest that miR-129-2 may function as a tumor suppressor
by inhibiting cell growth and promoting cell apoptosis in
glioma cells.
MiR-129-2 inhibits cell migration and invasion
in glioma cells in vitro
We then investigated the effect of miR-129-2 on cell mi-
gration and invasion of glioma cells, respectively. Tran-
swell assays with matrigel and wound-healing assays
indicated that the enhanced expression of miR-129-2 could
significantly inhibit cell invasion and migration compared
to control group in U373 and U87 cells (Fig. 3a, b). In
contrast, when endogenous miR-129-2 was silenced, the
cell invasion (Fig. 3a) and migration (Fig. 3b) were in-
creased. These results suggest that miR-129-2 may func-
tion as a tumor suppressor by inhibiting cell migration and
invasion in glioma cells.
MiR-129-2 directly targets HMGB1 and inhibits its
expression in glioma cells in vitro
To elucidate the molecular mechanism by which miR-129-
2 exerts its inhibitory effect on glioma cells, we predicted
potential targets of miR-129-2 and focused on HMGB1
considering the involvement of HMGB1 in the patho-
genesis of many human cancers. Besides, Western blot
analysis revealed that HMGB1 was significantly up-
regulated in glioma tumors compared with those in mat-
ched adjacent tissues (Fig. 4). To investigate if miR-129-2
directly targets HMGB1 in glioma cells, we amplified the
wild-type HMGB1 30UTR containing the predicted binding
sites of miR-129-2, and its mutant version by the binding
site mutagenesis was also constructed (Fig. 5a). They were
then cloned downstream to a luciferase reporter,
Fig. 1 MiR-129-2 was down-regulated in glioma tumors and cell
lines. a Boxplots to show the relative expression levels of miR-129-2
in 21 pairs of glioma tissues and their matched adjacent tissues
measured by RTq-PCR. b The relative expression levels of miR-129-
2 in normal neuronal cell line PHFG and four glioma cell lines (A172,
U251, U373, and U87). U6 was used as an internal control. *P\ 0.05
versus the normal
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respectively, named HMGB1-WT-30UTR and HMGB1-
Wut-30UTR vector. These two kinds of vectors were co-
transfected with miR-129-2 mimics, miR-129-2 inhibitor
(anti-miR-129-2 mimics), or their respective scrambled
controls into U373 and U87 cells, respectively. The
luciferase activity of miR-129-2 mimic transfected cells
was significantly decreased compared with control cells
(Fig. 5b). Moreover, miR-129-2-mediated repression of
luciferase activity was abolished by the mutant putative
binding sites (Fig. 5b). The above results suggest that miR-
Fig. 2 MiR-129-2 inhibits
glioma cell growth and
promotes cell apoptosis. After
lentivirus infection, the
expression of miR-129-2 (a),
the cell proliferation (b), the
percentage of cells in the G1,
G2, and S phases (c), and
apoptotic cell fractions (both
early and late apoptotic cells)
(d) were determined by
RTqPCR, MTT, and FCM
analysis, respectively.
*P\ 0.05 versus the control,
data shown are mean ± SD
c and d are for U373 cells, and
the similar results were also
found in U87 cells (data not
shown)
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Fig. 3 MiR-129-2 inhibits cell
migration and invasion in
glioma cells. U373 cell
migration (a) and invasion
(b) were determined by
transwell assays with matrigel
and wound-healing assays,
respectively. *P\ 0.05 versus
the control, data shown are
mean ± SD. The similar results
were also found in U87 cells
(data not shown)
Fig. 4 HMGB1 was up-
regulated in glioma tumors.
a Western blot to detect the
protein expression levels of
HMGB1 in 21 pairs of glioma
tumor tissues (T) and their
matched adjacent tissues (A).
b Quantification of the relative
expression based on Western
blot
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129-2 directly targets the 30UTR of HMGB1 in glioma
cells.
We then performed RTq-PCR analysis to examine the
inhibitory effect of miR-129-2 on endogenous HMGB1
expression in glioma cells. As shown in Fig. 5c, enforced
miR-129-2 significantly inhibited HMGB1 expression
levels, while reduced miR-129-2 improved HMGB1 levels
in U373 and U87 cells. Taken together, our data suggest
that miR-129-2 may inhibit HMGB1 expression by directly
targeting its 30UTR in glioma cells.
Knockdown of HMGB1 inhibits cell migration
and invasion of glioma cells in vitro
To investigate the functional roles of HMGB1 in glioma
cells, we knocked down HMGB1 in U373 and U87 cells
by HMGB1-specific small interfering RNAs (si-
HMGB1), which was confirmed by Western blot
(Fig. 6a). We then performed transwell assays with ma-
trigel (Fig. 6b) and wound-healing assays (Fig. 6c) and
found that knockdown of HMGB1 in U373 and U87
cells significantly inhibited cell invasion and migration
ability, respectively, which was similar to the effects of
miR-129-2 overexpression.
MiR-129-2 expression is epigenetically regulated
by DNA methylation in glioma cells
The above findings suggested that miR-129-2 is an im-
portant regulator in glioma cells. However, the regulatory
mechanism of miR-129-2 expression in glioma cells was
still unknown. As many miRNAs have been found to be
regulated by epigenetic modifications, especially DNA
methylation, we then analyzed the regulatory mechanism
of miR-129-2 expression from its promoter methylation.
We identified two CpG islands in the genomic region
spanning the miR-129-2 gene upstream (Fig. 7a). To fur-
ther investigate whether miR-129-2 was epigenetically
regulated in glioma cells, U373 and U87 cells were treated
with demethyltransferase inhibitor, 5-aza-20-deoxycytidine
(5-Aza-dC). DNA methylation analysis by bisulfite-cloning
and sequencing revealed that the upstream CpG islands of
the miR-129-2 gene were demethylated after 5-Aza-dC
treatment (Fig. 7b). RTq-PCR analysis revealed that the
expression of miR-129-2 was up-regulated in U373 (3.52-
fold) and U87 (3.67-fold) cells after the 5-Aza-dC treat-
ment compared with DMSO-treated control group
(Fig. 7c). This suggested that epigenetic factors could af-
fect miR-129-2 expression in glioma cells. Functional
Fig. 5 MiR-129-2 directly targets HMGB1 and inhibits its expres-
sion in glioma cells. a Predicted binding sequences of miR-129-2 in
the 30UTR of HMGB1. Mutation was generated in the seed region
(bold bases) of the 30UTR of HMGB1. b The repression of luciferase
activity by 30UTR of HMGB1 was dependent on miR-129-2. Mutated
30UTR of HMGB1 abrogated miR-129-2-mediated repression of
luciferase activity in U373 cells. The similar results were also found
in U87 cells (data not shown). c, d U373 and U87 cells were infected
with miR-129-2 or anti-miR-129-2 lentivirus, and the expression
levels of miR-129-2 and HMGB1 were analyzed by RTq-PCR.
*P\ 0.05 versus the control, data shown are mean ± SD
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analysis also revealed that demethylation-induced re-ex-
pression of miR-129-2 inhibited cell cycle, cell migration,
and invasion of U373 and U87 cells (Fig. 7d–f).
To further examine whether the methylation status of the
miR-129-2 upstream region was associated with glioma
development, MSP was performed in the 21 pairs of glioma
tissues and their matched adjacent tissues. We found that
DNA methylation in upstream regions of miR-129-2 fre-
quently occured in 21 tumor tissues (10 partially methy-
lated and 11 completely methylated), while the adjacent
tissues were all unmethylated (Fig. 7g).
Discussion
Glioma, the majority of malignant brain tumors, is one of
the most lethal forms of human cancer. Despite of im-
provements in glioma treatments, the molecular mechan-
isms underlying its pathology remain poorly understood. In
this study, we revealed that miR-129-2 was down-regulated
in human glioma cancer, partially due to its DNA promoter
hypermethylation. Further, functional studies demonstrated
that overexpression of miR-129-2 suppressed cell growth,
migration, and invasion and promoted cell apoptosis in the
glioma cells, at least partially through targeting the onco-
gene HMGB1.
In recent years, accumulated evidence revealed that
miRNAs play important roles in tumor development and
progression. Depending on their mRNA targets, miRNAs
can function as tumor suppressors or promoters [21]. MiR-
129 family members play an important role in several
cancers, including gastric cancer [8, 22], renal cell carci-
noma [23], medullary thyroid carcinomas [24], colorectal
cancer [25], hepatocellular cancer [26], and breast cancer
[27]. In these cancers, miR-129 family members are usu-
ally down-regulated and act as a tumor suppressor by de-
creasing cell growth, inducing apoptosis, or suppressing
cell migration and invasion. Consistent with previous re-
ports, our data suggest that miR-129-2 functions as a tumor
suppressor in glioma cells by inhibiting cell growth, mi-
gration, and invasion and promoting cell apoptosis. Fur-
ther, prediction and luciferase reporter assay revealed that
Fig. 6 Knockdown of HMGB1
inhibits cell migration and
invasion of glioma cells. a U373
cells were infected with
HMGB1-specific small
interfering RNAs (si-HMGB1)
and negative control (si-NC),
and the expression of HMGB1
was examined by Western
blotting. The similar results
were also found in U87 cells
(data not shown). b, c The effect
of HMGB1 knockdown on the
cell migration and invasion was
assessed by wound healing and
transwell with matrigel assays,
respectively. *P\ 0.05 versus
the control, data shown are
mean ± SD
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miR-129-2 could directly target HMGB1 and inhibited its
expression.
Recent findings have revealed that HMGB1 dysfunction
contributes to cancer initiation and development [28].
HMGB1 overexpression has been observed in many can-
cers such as colon cancer [29], gastrointestinal stromal
tumors [30], melanoma [31], hepatocellular carcinoma
[32], and glioma [33], and HMGB1 promotes cell growth
and/or migration during the above tumor pathology. In
glioma cells, inhibition of HMGB1 was found to suppress
the cell growth and migration in vitro [33]. In this study,
we inhibited HMGB1 expression by siRNA in U373 and
U87 cells and found that knockdown of HMGB1 inhibited
cell migration and invasion of glioma cells in vitro, which
is consistent with previous report [33]. It has been reported
that HMGB1 can induce the growth and migration of cells
via its intracellular signaling pathways including NF-jB,
MAPK, and ERK [34, 35]. HMGB1 was found to up-reg-
ulate the expression of MMP-9, which belongs to matrix
metalloproteinases (MMPs) involved in the initiation, in-
vasion, and metastasis of many kinds of cancers, in glioma
and gastric cancer cells [33, 36], which may explain its
association with invasion and metastasis of glioma tumor.
Taken together, the validated involvement of miR-129-1/
HMGB1 link in glioma cells may provide potential to use
miR-129-2 and HMGB1 as therapeutic targets for glioma.
Fig. 7 MiR-129-2 expression is
epigenetically regulated by
DNA methylation in glioma
cells. a A schematic illustration
of CpG islands in the upstream
region of miR-129-2 gene and
the primers for MSP or BSP.
b Bisulfite-sequencing PCR
detected the methylation status
among U373 and U87 cells
before and after 5-Aza-dC
treatment. Columns indicate
CpG dinucleotides 1-22, and
horizontal lines represent clones
1-20. Black dots symbolize
methylated CpGs, and white
dots symbolize unmethylated
CpGs. c Effect of 5-Aza-dC
treatment on miR-129-2
expression in U373 and U87
cells tested by RTq-PCR. d, e,
f Effects of 5-Aza-dC treatment
on cell cycle, cell migration,
and invasion of U373 and U87
cells, f for U373, and the similar
result was also found in U87
cells (data not shown). g MSP
results of miR-129-2
methylation in the 21 pairs of
glioma tissues (Tumor) and
their matched adjacent tissues
(Adjacent). M = PCR products
amplified by MSP specific for
methylated DNA, U = PCR
products amplified by MSP
specific for unmethylated DNA
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Epigenetic modifications including DNA hypermethy-
lation are closely associated with gene inactivation. Many
reports have revealed that promoter hypermethylation in-
duced down-regulation of tumor suppressive miRNAs
closely correlates with carcinogenesis [37–39]. Our data
demonstrated that the hypermethylation of the CpG island
upstream of miR-129-2 led to the down-regulation of miR-
129-2 in glioma patients. Moreover, demethylation of miR-
129-2 by 5-Aza-dC treatment increased miR-129-2 ex-
pression in glioma cells and resulted in significant in-
hibitory effects on cell cycle, migration, and invasion.
Based on these findings, the methylation status of miR-
129-2 may be employed as a potential biomarker in glioma.
In conclusion, our study suggests that miR-129-2 is
down-regulated by DNA methylation and functions as a
tumor suppressor by targeting HMGB1 in glioma cells.
Reintroducing expression of miR-129-2 in glioma cells
suppresses cell growth, migration, and invasion and pro-
motes cell apoptosis, which may provide a novel
therapeutic strategy for treatment of glioma.
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